Nykode initiates clinical study of "pan-variant" Covid-19 vaccine
![Michael Engsig, CEO of Nykode Therapeutics | Photo: Nykode Therapeutics / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13595698.ece/ALTERNATES/schema-16_9/doc7j18vkqgm8oan6zwjeb.jpg)
Norwegian biotech firm Nykode Therapeutics, formerly known as Vaccibody, has dosed the first patient in a phase I/II trial involving its T-cell focused vaccine candidate, dubbed VB-D-01, designed to address new Covid-19 variants including Omicron, which are cause for concern the world over.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Denmark defends controversial Covid-19 pill
For subscribers
Bavarian Nordic: We can adapt our vaccine if necessary
For subscribers